Dianthus Therapeutics-2026-JPM.pdf

1、Advancing a leading autoimmune-focused companyJanuary 12,2026 2Forward-looking statementsCertain statements in this presentation,other than purely historical information,may constitute“forward-looking statements”within the meaning of the federal securities laws,including for purposes of the safe har

2、bor provisions under the United States Private Securities Litigation Reform Act of 1995,express or implied statements regarding future plans and prospects,including statements regarding the expectations or plans for discovery,preclinical studies,clinical trials and research and development programs,

3、in particular with respect to claseprubart and DNTH212,and any developments or results in connection therewith,including the target product profile and administration of claseprubart and DNTH212;the anticipated timing of the initiation and results from those studies and trials;expectations regarding

4、 the clinical trial designs or indications;expectations regarding the time period over which the Companys capital resources are expected to be sufficient to fund its anticipated operations;and expectations regarding market size,patient population size,and potential opportunities for complement thera

5、pies,in particular with respect to claseprubart and DNTH212.Claseprubart and DNTH212 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide.The words“opportunity,”“potential,”“milestones,”“runway,”“will,”“anticipate,”“achieve,”“near-term,”“catal

6、ysts,”“pursue,”“pipeline,”“believe,”“continue,”“could,”“estimate,”“expect,”“intend,”“may,”“might,”“plan,”“possible,”“predict,”“project,”“should,”“strive,”“would,”“aim,”“target,”“commit,”and similar expressions(including the negatives of these terms or variations of them)generally identify forward-lo